康莱特合并化疗治疗晚期非小细胞肺癌的临床观察

Clinical observation of Kanglaite combined Chemotherapy in the Treatment of Advanced non-small cell lung carcinoma

为观察康莱特联合异长春花碱(NVB)、顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。98例中晚期非小细胞肺癌,其中进行康莱特、DDP、NVB治疗的50例(A组),进行DDP、NVB治疗的48例(B组),其中可评价病例62人,A组30人,B组32人。康莱特100mL,1次/d,NVB25mg/m2,d1、d8;DDP40mg/m2,d1～d3,21d为1周期,至少3个周期。A、B两组有效率分别为46.7%(14/30)和37.5%(12/32),两者差异有统计学意义,χ2=4.659,P=0.034。主要的毒副反应骨髓抑制和胃肠道反应,其中白细胞减少B组较A组明显,χ2=6.847,P=0.009,其他无统计学意义。A组较B组生活质量高,且对淋巴细胞亚群的影响不大。初步研究结果提示,康莱特能提高化疗的疗效,减轻化疗的副作用,且可以提高生活质量,有免疫保护作用。

To evaluate the efficacy and toxicity of kangLaiTe combined NVB、DDP and NVB combined DDP in the treatment of advanced non-small cell lung carcinoma (NSCLC). 50 patients with NSCLC were treated with kanglaite plus NVB and DDP, 48 patients were treated with NVB and DDP. Kanglaite was given in a dosage of 100 mL, every day. NVB was gived in a dosage of 25 mg/m 2 on day 1 and 8, and DDP in a dosage of 40 mg/m 2 on day 1 to 3. Twenty-one days was one circal, with at least three circals. 30 patients for A and 32 patients for B are evaluated. The response rate of 50 patients treated with Kanglaite combined NVB, DDP was 46.7%,the control group was 37.5%. The main toxocities were myelosuppression and troubles in gastrointestinal tract. Kanglaite can improve the efficacy of Chemotherapy and reduce the toxocities,improve the live quality and protect immunity function.